Clinical Value of 68Ga-DOTA-Bombesin PET/CT Compared With 18F-FDG PET/CT in the Staging of Breast Cancer
Authors:
- Mehmet Can BalogluMBMehmet Can Baloglu
- Rahime ŞahinRŞRahime Şahin
- Zehranur TosunogluZTZehranur Tosunoglu
- Ahmet Ertugrul OzturkAOAhmet Ertugrul Ozturk
- Ömer Faruk ŞahinÖŞÖmer Faruk Şahin
- Ediz BeyhanEBEdiz Beyhan
- Özge Erol FenerciogluÖFÖzge Erol Fenercioglu
- Göksel AlcinGAGöksel Alcin
- Tevfik Fikret CermikTCTevfik Fikret Cermik
- Çiğdem Usul AfsarÇAÇiğdem Usul Afsar
- Esra ArslanEAEsra Arslan
- 18 June 2026
- journal article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (9) , e759-e767
Abstract
Aim: To prospectively evaluate the diagnostic performance of 68 Ga-DOTA-Bombesin PET/CT compared with 18 F-FDG PET/CT in breast cancer (BC), emphasizing its utility across molecular subtypes and nodal staging. Patients and Methods: Twenty-four patients with biopsy-proven BC who underwent both 68 Ga-DOTA-Bombesin and 18 F-FDG PET/CT were included. Imaging findings were analyzed on a per-lesion and per-patient basis for primary tumor detection, axillary lymph-node involvement, and distant metastases. Quantitative parameters (SUVmax, MTV, and tumor-to-background ratios) were compared across histopathologic and receptor subgroups, with histopathology as the reference standard. Results: 68 Ga-DOTA-Bombesin visualized 92.3% of primary tumors, achieving comparable sensitivity to 18 F-FDG (84.6%) but higher specificity in nodal staging (100% vs. 53.8%). Bombesin uptake correlated strongly with estrogen receptor positivity and a lower Ki-67 index ( P 68 Ga-DOTA-Bombesin PET/CT provides a receptor-specific imaging approach in BC, showing complementary strengths to 18 F-FDG, particularly in hormone-receptor–positive and low-proliferation tumors. Its superior nodal specificity and theranostic potential support further evaluation of GRPR-targeted imaging and therapy in personalized BC management.Keywords
This publication has 38 references indexed in Scilit:
- [18F]FDG PET/CT: EANM procedure guidelines for tumour imaging: version 3.0The EANM Journal, 2025
- ER-Targeted PET for Initial Staging and Suspected Recurrence in ER-Positive Breast CancerJAMA Network Open, 2024
- Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer ManagementPET Clinics, 2024
- Breast cancer: initial workup and staging with FDG PET/CTClinical and Translational Imaging, 2021
- Current Guidelines and Gaps in Breast Cancer ScreeningJournal of the American College of Radiology, 2020
- First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node MetastasisJAMA, 2017
- 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015